Reem Rafik AlOlaby1, Stefan R Sweha1, Marisol Silva1, Blythe Durbin-Johnson2, Carolyn M Yrigollen1, Dalyir Pretto1, Randi J Hagerman3, Flora Tassone4. 1. Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, CA, USA. 2. Department of Biostatistics, University of California, Davis, School of Medicine, Davis, CA, USA. 3. MIND Institute, University of California Davis Medical Center, Davis, CA, USA; Department of Pediatrics, University of California, Davis, School of Medicine, Davis, CA, USA. 4. Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, CA, USA; MIND Institute, University of California Davis Medical Center, Davis, CA, USA. Electronic address: ftassone@ucdavis.edu.
Abstract
OBJECTIVES: Several neurotransmitters involved in brain development are altered in fragile X syndrome (FXS), the most common monogenic cause of autism spectrum disorder (ASD). Serotonin plays a vital role in synaptogenesis and postnatal brain development. Deficits in serotonin synthesis and abnormal neurogenesis were shown in young children with autism, suggesting that treating within the first years of life with a selective serotonin reuptake inhibitor might be the most effective time. In this study we aimed to identify molecular biomarkers involved in the serotonergic pathway that could predict the response to sertraline treatment in young children with FXS. METHODS: Genotypes were determined for several genes involved in serotonergic pathway in 51 children with FXS, ages 24-72months. Correlations between genotypes and deviations from baseline in primary and secondary outcome measures were modeled using linear regression models. RESULTS: A significant association was observed between a BDNF polymorphism and improvements for several clinical measures, including the Clinical Global Impression scale (P=0.008) and the cognitive T score (P=0.017) in those treated with sertraline compared to those in the placebo group. Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study. CONCLUSION: This study shows that polymorphisms of genes involved in the serotonergic pathway could play a potential role in predicting response to sertraline treatment in young children with FXS. Larger studies are warranted to confirm these initial findings.
RCT Entities:
OBJECTIVES: Several neurotransmitters involved in brain development are altered in fragile X syndrome (FXS), the most common monogenic cause of autism spectrum disorder (ASD). Serotonin plays a vital role in synaptogenesis and postnatal brain development. Deficits in serotonin synthesis and abnormal neurogenesis were shown in young children with autism, suggesting that treating within the first years of life with a selective serotonin reuptake inhibitor might be the most effective time. In this study we aimed to identify molecular biomarkers involved in the serotonergic pathway that could predict the response to sertraline treatment in young children with FXS. METHODS: Genotypes were determined for several genes involved in serotonergic pathway in 51 children with FXS, ages 24-72months. Correlations between genotypes and deviations from baseline in primary and secondary outcome measures were modeled using linear regression models. RESULTS: A significant association was observed between a BDNF polymorphism and improvements for several clinical measures, including the Clinical Global Impression scale (P=0.008) and the cognitive T score (P=0.017) in those treated with sertraline compared to those in the placebo group. Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study. CONCLUSION: This study shows that polymorphisms of genes involved in the serotonergic pathway could play a potential role in predicting response to sertraline treatment in young children with FXS. Larger studies are warranted to confirm these initial findings.
Authors: Zoë H Brett; Kathryn L Humphreys; Anna T Smyke; Mary Margaret Gleason; Charles A Nelson; Charles H Zeanah; Nathan A Fox; Stacy S Drury Journal: Dev Psychopathol Date: 2015-02
Authors: Laura Greiss Hess; Sarah E Fitzpatrick; Danh V Nguyen; Yanjun Chen; Kimberly N Gaul; Andrea Schneider; Kerrie Lemons Chitwood; Marwa Abd Al Azaim Eldeeb; Jonathan Polussa; David Hessl; Susan Rivera; Randi J Hagerman Journal: J Dev Behav Pediatr Date: 2016-10 Impact factor: 2.225
Authors: Kim L Felmingham; Carol Dobson-Stone; Peter R Schofield; Gregory J Quirk; Richard A Bryant Journal: Biol Psychiatry Date: 2013-01-08 Impact factor: 13.382
Authors: Tri Indah Winarni; Weerasak Chonchaiya; Evan Adams; Jacky Au; Yi Mu; Susan M Rivera; Danh V Nguyen; Randi J Hagerman Journal: Autism Res Treat Date: 2012-05-31
Authors: Jessica Klusek; Roger Newman-Norlund; Amanda J Fairchild; Sarah Newman-Norlund; Sara Sayers; Jill C Stewart; Elizabeth Berry-Kravis; Julius Fridriksson Journal: Arch Gerontol Geriatr Date: 2022-08-12 Impact factor: 4.163
Authors: Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller Journal: Can J Psychiatry Date: 2020-11-23 Impact factor: 5.321
Authors: Angela John Thurman; Laura A Potter; Kyoungmi Kim; Flora Tassone; Amy Banasik; Sarah Nelson Potter; Lauren Bullard; Vivian Nguyen; Andrea McDuffie; Randi Hagerman; Leonard Abbeduto Journal: J Neurodev Disord Date: 2020-04-22 Impact factor: 4.025
Authors: Laura A Potter; Danielle A Scholze; Hazel Maridith B Biag; Andrea Schneider; Yanjun Chen; Danh V Nguyen; Akash Rajaratnam; Susan M Rivera; Patrick S Dwyer; Flora Tassone; Reem R Al Olaby; Nimrah S Choudhary; Maria J Salcedo-Arellano; Randi J Hagerman Journal: Front Psychiatry Date: 2019-11-06 Impact factor: 4.157
Authors: Hazel Maridith B Biag; Laura A Potter; Victoria Wilkins; Sumra Afzal; Alexis Rosvall; Maria Jimena Salcedo-Arellano; Akash Rajaratnam; Ramiro Manzano-Nunez; Andrea Schneider; Flora Tassone; Susan M Rivera; Randi J Hagerman Journal: Mol Genet Genomic Med Date: 2019-09-14 Impact factor: 2.183